Wedbush Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock Price

IDEAYA Biosciences (NASDAQ:IDYA) had its price target upped by Wedbush from $49.00 to $52.00 in a research note released on Wednesday, MarketBeat Ratings reports. Wedbush currently has an outperform rating on the stock.

Several other research analysts have also recently commented on the company. Wall Street Zen upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 9th. JPMorgan Chase & Co. upped their target price on IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, January 22nd. Royal Bank Of Canada raised their price target on shares of IDEAYA Biosciences from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Finally, Mizuho lifted their price target on shares of IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 11th. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.60.

IDEAYA Biosciences Stock Performance

IDYA opened at $30.92 on Wednesday. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $39.28. The firm has a 50 day moving average price of $34.25 and a 200 day moving average price of $30.44. The company has a market cap of $2.71 billion, a PE ratio of -23.60 and a beta of 0.10.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.09. The company had revenue of $21.75 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same period last year, the business earned ($1.49) earnings per share. The company’s revenue for the quarter was up 55.7% compared to the same quarter last year. On average, sell-side analysts predict that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its holdings in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of IDEAYA Biosciences during the 3rd quarter worth about $38,000. ANTIPODES PARTNERS Ltd grew its holdings in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares in the last quarter. Abich Financial Wealth Management LLC acquired a new stake in IDEAYA Biosciences during the third quarter worth $58,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in IDEAYA Biosciences in the second quarter valued at about $61,000. Institutional investors own 98.29% of the company’s stock.

Key Stories Impacting IDEAYA Biosciences

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: Q4 / FY2025 results beat expectations: EPS loss was narrower than consensus (‑$0.94 vs. ‑$1.03 est.) and revenue came in well above estimates at $21.75M (vs. ~$5.95M est.), with revenue up ~56% year‑over‑year — a tangible near-term fundamental beat. Q4 Press Release
• Positive Sentiment: Pipeline and readout timing bolsters near-term catalyst visibility: 130 required PFS events were confirmed by BICR in the Phase 2/3 OptimUM‑02 darovasertib + crizotinib trial and topline results are expected by roughly the last week of March; darovasertib is planned for three randomized Phase 3 registrational trials by H1 2026. Business Update / PR Newswire
• Positive Sentiment: ADC program (IDE849) progress and milestones: company expects to initiate a registrational IDE849 monotherapy study in 2L+ SCLC/NEC by end of 2026 and to provide preliminary IDE849 Phase 1 data by year‑end — potential medium‑term value drivers if clinical data are positive. Business Update / PR Newswire
• Positive Sentiment: Strong balance sheet: ~ $1.05B in cash, cash equivalents and marketable securities as of 12/31/2025, which management says should fund operations into 2030 — lowers near‑term financing risk. Business Update / PR Newswire
• Positive Sentiment: Analyst price-target lifts: Wedbush raised its target to $52 (outperform), Guggenheim reaffirmed buy with $50 PT, and RBC reaffirmed outperform with a $49 PT — these raise upside expectations and can support investor sentiment. Wedbush note Guggenheim note RBC / Benzinga
• Neutral Sentiment: Management presentation at Citi’s 2026 Virtual Oncology Leadership Summit provided additional corporate and program-level color (transcript available) but contained no new timing surprises beyond the company release. Citi Summit Transcript

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.